Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
出版年份 2009 全文链接
标题
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
作者
关键词
-
出版物
BLOOD
Volume 114, Issue 27, Pages 5426-5435
出版商
American Society of Hematology
发表日期
2009-10-31
DOI
10.1182/blood-2009-08-215939
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene
- (2010) Marta Barańska et al. JOURNAL OF APPLIED GENETICS
- Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
- (2009) M. C. Muller et al. BLOOD
- Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
- (2009) E. Jabbour et al. BLOOD
- Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
- (2009) S. Soverini et al. BLOOD
- Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
- (2009) Jane F. Apperley et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2009) Timothy Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
- (2008) E. Jabbour et al. BLOOD
- The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene
- (2008) P.-Y. Wang et al. BLOOD
- Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL
- (2008) C. G. Mullighan et al. GENES & DEVELOPMENT
- Mesenchymal stem cells: the fibroblasts' new clothes?
- (2008) M. A. Haniffa et al. HAEMATOLOGICA
- Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression
- (2008) Jamshid S. Khorashad et al. JOURNAL OF CLINICAL ONCOLOGY
- Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
- (2008) Neil P. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase
- (2008) Ji Wu et al. JNCI-Journal of the National Cancer Institute
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now